A photo of Basilia Zingarelli.

Director, Basic Science Research

Professor, UC Department of Pediatrics


Biography & Affiliation


Basilia Zingarelli, MD, PhD, came to Cincinnati Children's Hospital Medical Center in 1995 as a post-doctoral research fellow in Critical Care Medicine. She joined the faculty of the University of Cincinnati College of Medicine in 1997.

Dr. Zingarelli graduated from the Medical School of the University of Messina in Italy in 1990. She also obtained a doctorate in experimental medicine in 1997 and attended a residency in medical toxicology at the University of Messina from 1990 to 1992.

Dr. Zingarelli now directs the basic science research in the Division of Critical Care Medicine. She directs an NIH-funded research laboratory focused on the pathogenetic mechanisms of organ injury during sepsis, trauma and hemorrhage and coordinates basic science and clinical translational research projects related to other critical care conditions.

Dr. Zingarelli serves on the Executive Council of the Shock Society, a well-established international association of clinical and research scientists in the field of shock and trauma, and serves as associate editor for the journal Shock. She also serves as permanent and ad hoc member on a number of study sections at the National Institutes of Health.

Research Interests

Signal transduction mechanisms regulating the inflammatory response in sepsis, hemorrhage, ischemia and reperfusion injury; inflammatory bowel disease with focus on the role of the nuclear enzyme poly (ADP-ribose) polymerase and the nuclear peroxisome proliferator activated receptors; development of novel therapeutic approaches for the treatment of sepsis and trauma

Academic Affiliation

Professor, UC Department of Pediatrics


Critical Care


MD: School of Medicine, University of Messina, Italy, 1990.

PhD: Experimental Medicine, School of Medicine, University of Messina, Italy, 1997.

Residency: Medical Toxicology, School of Medicine, University of Messina, Italy, 1990-1992.

Certification: General Medicine (Italian), 1990.


Hepatocyte-Specific Deletion of AMPKα1 Results in Worse Outcomes in Mice Subjected to Sepsis in a Sex-Specific Manner. Kikuchi, S; Piraino, G; O'Connor, M; Wolfe, V; Ridings, K; Lahni, P; Zingarelli, B. Frontiers in Immunology. 2020; 11.

Exosomes from endothelial progenitor cells improve outcomes of the lipopolysaccharide-induced acute lung injury. Zhou, Y; Li, P; Goodwin, AJ; Cook, JA; Halushka, PV; Chang, E; Zingarelli, B; Fan, H. Critical Care (UK). 2019; 23.

The olfactomedin-4 positive neutrophil has a role in murine intestinal ischemia/reperfusion injury. Levinsky, NC; Mallela, J; Opoka, AM; Harmon, K; Lewis, HV; Zingarelli, B; Wong, HR; Alder, MN. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2019; 33:13660-13668.

Activation of AMP-Activated Protein Kinase by A769662 Ameliorates Sepsis-Induced Acute Lung Injury in Adult Mice. Kitzmiller, L; Ledford, JR; Hake, PW; O'Connor, M; Piraino, G; Zingarelli, B. Shock. 2019; 52:540-549.

Age-Dependent Myocardial Dysfunction in Critically Ill Patients: Role of Mitochondrial Dysfunction. Lautz, AJ; Zingarelli, B. International Journal of Molecular Sciences. 2019; 20:3523-3523.

PART I: MINIMUM QUALITY THRESHOLD IN PRECLINICAL SEPSIS STUDIES (MQTiPSS) FOR STUDY DESIGN AND HUMANE MODELING ENDPOINTS. Zingarelli, B; Coopersmith, CM; Drechsler, S; Efron, P; Marshall, JC; Moldawer, L; Wiersinga, WJ; Xiao, X; Osuchowski, MF; Thiemermann, C. Shock. 2019; 51:10-22.

The Response to the Letter to the Editor Titled: "Is Triple Self-plagiarism "OK " If Only Made Transparent?'' by Volker R Jacobs, MD, MBA. Osuchowski, MF; Hellman, J; Huber-Lang, M; Libert, C; Remick, DG; Thiemermann, C; Zingarelli, B. Shock. 2019; 51:140-141.

Fli-1 Governs Pericyte Dysfunction in a Murine Model of Sepsis. Li, P; Zhou, Y; Goodwin, AJ; Cook, JA; Halushka, PV; Zhang, XK; Wilson, CL; Schnapp, LM; Zingarelli, B; Fan, H. Journal of Infectious Diseases. 2018; 218:1995-2005.

Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Osuchowski, MF; Ayala, A; Bahrami, S; Bauer, M; Boros, M; Cavaillon, J; Chaudry, IH; Coopersmith, CM; Deutschman, C; Drechsler, S; et al. Intensive Care Medicine Experimental. 2018; 6.

Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial. Kaplan, JM; Zingarelli, B; Krallman, K; Girdwood, ST; Lagory, D; Mizuno, T; Fei, L; Wong, HR; Vinks, AA. Intensive Care Medicine. 2018; 44:2006-2008.